Carbon ion radiation with chemotherapy for thymus tumors not treatable by surgery
Tests carbon ion radiation plus chemotherapy for thymic epithelial tumors.
Key facts
- Who runs it
- Jian Chen
- Where
- China1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
- Status
- Recruiting
- Phase
- Phase 2
- People taking part
- 48 people, planned
- Started
- 26 Jan 2024
- Expected to end
- 31 Dec 2029
- Type of study
- Interventional
- Treatments tested
- carbon ion radiotherapy
- Record updated
- 13 June 2025
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with thymic epithelial tumor (thymoma or thymic carcinoma) that cannot be removed by surgery. They will get carbon ion radiotherapy with platinum-based chemotherapy.
- Age
- 18 to 70 years
- Sex
- All sexes
- Disease stage
- Locally advanced or advanced thymic epithelial tumor, confirmed by tissue test, that cannot be operated on. Lesions must be measurable on scans. All visible lesions must fit inside the radiation area. ECOG score 0-2, meaning able to care for yourself. Expected survival of at least 6 months.
- Earlier treatment
- People who have had radiation therapy to the chest or radioactive seed implants in the chest cannot join.
Main reasons for not taking part
- Another cancer that is not under control
- Large amount of fluid around the lungs or heart
- Pacemaker or metal implants that could affect or be affected by the radiation
- Pregnancy or breastfeeding
- HIV positive, active syphilis, or hepatitis needing antiviral treatment that cannot be given
The registry criteria, word for word
Show all 16 criteriaShow less
Who can take part
- Patients with inoperable locally advanced or advanced thymic epithelial tumor who have been confirmed pathologically, and have not received thoracic radiation therapy before coming to our hospital, and have radiologically evaluable lesions, and all visible lesions can be included in the radiation target area during this treatment
- Between the ages of 18 and 70
- Sign the informed consent
- ECOG general status score of 0-2
- The expected survival is greater than or equal to 6 months
- Adequate organ function: 1). Blood function: absolute neutrophil count (ANC) ≥1.5 x 109/L, platelet count ≥80 x 109/L, hemoglobin ≥9 g/dL 2). Lung function: FEV1>25%, DLCO>25% 3). Cardiac function: no serious pulmonary hypertension, cardiovascular and cerebrovascular diseases, peripheral vascular diseases, serious chronic heart disease and other complications that may affect radiotherapy.4). Adequate liver function: total bilirubin <1.5 times the upper limit of normal value, and AST, ALT<2 times the upper limit of normal value. 5). Adequate renal function: serum creatinine ≤1.5 times the upper limit of normal or calculated creatinine clearance ≥50 ml /min, and urinary protein <2+. Patients with a baseline urinary protein level of 2+ or more should have a 24-hour urine collection and evidence of a 24-hour urinary protein level of 1g or less
Who cannot take part
- Patient whose particle radiotherapy plan cannot meet the minimum target dose coverage and dose volume limitation requirements, or cannot meet the dose constrains of normal tissue or organs
- Chest radiation therapy or radioactive particle implantation history
- HIV positive. Hepatitis virus replication phase, need to receive antiviral therapy, but because of concomitant disease cannot receive antiviral therapy. Active stage of syphilis
- Complicated with other malignant tumors that have not been controlled
- Cardiac pacemakers or other internal metal prosthesis implants that may be affected by high-energy radiation or may affect the dose distribution to the radiation target area
- A history of mental illness may hinder the completion of treatment
- With serious comorbidity that may interfere with radiotherapy, including: (a) Acute infectious diseases or acute active phase of chronic infection. b) Unstable angina pectoris, congestive heart failure, myocardial infarction that has been hospitalized in the past 6 months. c) Exacerbations of chronic obstructive pulmonary disease or other respiratory conditions requiring hospitalization. d) Severely impaired immune function. e) Diseases with excessive sensitivity to radiation such as ataxia telangiectasia. f) Other diseases that may affect particle radiotherapy
- Pregnancy (confirmed by serum or urine β-HCG test) or lactation period
- With large quantity of pleural effusion or pericardial effusion
- Other circumstances that the physician considers inappropriate to participate in clinical study
The main criteria, as questions
These questions come from the eligibility criteria published for this trial. They help you read the criteria and prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.
- Are you between 18 and 70 years old?
This trial is currently available in China.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
To observe the efficacy of carbon ion radiotherapy combined with chemotherapy in the treatment of inoperable locally advanced or advanced (all visible lesions can be included in the radiation target area in this treatment) primary thymic epithelial tumor who have no thorax radiotherapy histroy. The patients will receive 72GyE/18fractions of carbon ion radiotherapy. Combined with platinum-containing schemes (including etoposide combined with cisplatin or carboplatin or loplatin or nedaplatin, paclitaxel combined with cisplatin or carboplatin or loplatin or nedaplatin, etc.); Docetaxel combined with cisplatin or carboplatin or loplatin or nedaplatin) for at least 4 cycles. Progression-free survival, local control rate, overall survival and toxicity were calculated.
The group in the trial
- Study armTreatment being tested
The patients received 72GyE/18 fractions of carbon ion radiotherapy. Combined with platinum-containing schemes (including etoposide combined with cisplatin or carboplatin or loplatin or nedaplatin, paclitaxel combined with cisplatin or carboplatin or loplatin or nedaplatin, etc.); Docetaxel combined with cisplatin or carboplatin or loplatin or nedaplatin) for at least 4 cycles
Treatment: carbon ion radiotherapy
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Prospective Phase II Clinical Study of Carbon Ion Radiotherapy Combined With Chemotherapy for Thymic Epithelial Tumors
- Plain-language title
- Carbon ion radiation with chemotherapy for thymus tumors not treatable by surgeryGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 15 November 2026.
- Criteria questions
- Built from NCT06186726, who can take part
- Record updated
- 13 June 2025